Tempus AI’s risky bet could come with a real Big Tech payoff
It’s been a choppy run for AI stocks lately as investors grow more skeptical of the sector’s hype-driven narratives. But this week started on firmer footing for the industry, putting Tempus AI back on retail radar screens in the process.
The precision-medicine firm has seen plenty of volatility, but institutional analysts still see meaningful long-term potential.
What TEM stock has going for it
AI healthcare remains one of the market’s most volatile corners. Still, several data points explain why some firms continue to lean bullish:
- Baird initiated coverage giving TEM an “outperform” rating and a $59 price target
- The company posted a record $1.1B total contract value at year-end 2025
- Application revenue was 31% higher year-over-year
- New AI tools like Paige Predict are expanding diagnostic capabilities
Strategic partnerships with NYU Langone Health and Northwestern Medicine sweeten the pot even more.
Institutional activity also stands out, with ARK Invest boosting its stake to more than 7.5 million shares and firms from State Street Corporation to AQR Capital Management adding exposure. Zooming out, the AI precision-medicine market is projected to see a compound annual growth rate of roughly 34%, which would give Tempus a lengthy runway if execution holds up.
The backdrop does contain ample risk, though. Stock is down more than 33% over six months and the company is still unprofitable with negative EPS. And Baird itself labeled TEM a “speculative risk.”
Looking ahead to earnings
Tempus reports Q4 results next week, and expectations are modest. Wall Street consensus labels it a hold with price targets well above the $52.56-per-share the stock was trading at after Tuesday’s 1%+ gains.
Sentiment is pretty well divided between “buy” and “hold,” with investors looking for clues from several earnings report catalysts, including profitability updates, data-licensing revenue growth, Pixel platform adoption updates, and changes in forward guidance.
Insider selling hit about $49M over 90 days, adding another wrinkle to the outlook, though insiders still own about 26% of shares.
TEM represents a high-risk, high-reward gamble that has defined plenty of other early AI cycles in recent years. The runway for soaring growth is real, but investors understand execution is the only thing that will keep it airborne.